Health - Written Evidence [Back to Report]
Here you can browse the Written Evidence ordered by the House of Commons to be printed 26 April 2007.
Written evidence
CONTENTS
Evidence submitted by the Department of Health
(NICE 01)
Evidence submitted by the National Institute
for Health and Clinical Excellence (NICE 71)
Evidence submitted by the Academy of Medical
Sciences (NICE 39)
Evidence submitted by the Alzheimer's Society
(NICE 70)
Evidence submitted by the American Pharmaceutical
Group (NICE 89)
Evidence submitted by Amgen (NICE 58)
Evidence submitted by Archimedes (NICE 68)
Evidence submitted by the Arthritis and Musculoskeletal
Alliance (NICE 97)
Evidence submitted by the Association of
British Healthcare Industries (NICE 85)
Evidence submitted by the Association of
the British Pharmaceutical Industry (NICE 72)
Evidence submitted by AstraZeneca (NICE 33)
Evidence submitted by beat (NICE 06)
Evidence submitted by the Bioindustry Association
(BIA) (NICE 93)
Evidence submitted by Bowel Cancer UK (NICE
38)
Evidence submitted by Breakthrough Breast
Cancer (NICE 60)
Evidence submitted by Bristol-Myers Squibb
Pharmaceuticals Ltd (NICE 51)
Evidence submitted by the British Association
for Counselling and Psychotherapy (NICE 92)
Evidence submitted by the British Medical
Association (NICE 95)
Evidence submitted by the British Society
for Rheumatology (NICE 53)
Evidence submitted by Cancerbackup (NICE
42)
Evidence submitted by Cancer Research UK
(NICE 67)
Evidence submitted by the Roy Castle Lung
Cancer Foundation (NICE 24)
Evidence submitted by the Continence Foundation
(NICE 23)
Evidence submitted by the Cystic Fibrosis
Trust (NICE 43)
Evidence submitted by Deltex Medical (NICE
87)
Evidence submitted by Diabetes UK (NICE 78)
Evidence submitted by the Joint Epilepsy
Council of the UK and Ireland (NICE 40)
Evidence submitted by the Ethical Medicines
Industry Group (NICE 79)
Evidence submitted by the European Medicines
Group (NICE 84)
Evidence submitted by FEmISA (NICE 49)
Evidence submitted by GlaxoSmithKline (NICE
86)
Evidence submitted by Help the Aged (NICE
11)
Evidence submitted by the Hepatitis C Trust
(NICE 29)
Evidence submitted by the Improving Surgical
Outcomes Group (ISOG) (NICE 75)
Evidence submitted by the Institute for Innovation
& Valuation in Health Care (NICE 18)
Evidence submitted by Johnson & Johnson
(NICE 74)
Evidence submitted by KCI Medical UK (NICE
14)
Evidence submitted by Kidney Cancer UK (NICE
90)
Evidence submitted by Leukaemia CARE (NICE
64)
Evidence submitted by Lifeblood: The Thrombosis
Charity (NICE 35)
Evidence submitted by Lilly (NICE 94)
Evidence submitted by the 25% ME Group (NICE
19)
Evidence submitted by the ME Association
(NICE 28)
Evidence submitted by the Medical Technology
Group (NICE 52)
Evidence submitted by Medtronic Ltd (NICE
15)
Evidence submitted by Merck Serono (NICE
77)
Evidence submitted by the MS Society (NICE
65)
Evidence submitted by the Motor Neurone Disease
Association (NICE 25)
Evidence submitted by Myeloma UK (NICE 30)
Evidence submitted by UK Myeloma Forum (NICE
96)
Evidence submitted by the National Childbirth
Trust (NICE 27)
Evidence submitted by the National Infertility
Awareness Campaign (NICE 44)
Evidence submitted by the National Osteoporosis
Society (NICE 69)
Evidence submitted by the National Rheumatoid
Arthritis Society (NICE 82)
Evidence submitted by the NHS Confederation
(NICE 73)
Evidence submitted by Novartis Pharmaceuticals
UK Ltd (NICE 59)
Evidence submitted by Pfizer (NICE 47)
Evidence submitted by The British Psychological
Society (NICE 81)
Evidence submitted by Rarer Cancers Forum
(NICE 34)
Evidence submitted by Roche Pharmaceuticals
(NICE 55)
Evidence submitted by the Royal College of
Midwives (NICE 62)
Evidence submitted by the Royal College of
Nursing (NICE 100)
Evidence submitted by the Royal College of
Physicians of Edinburgh (NICE 45)
Evidence submitted by the Royal College of
Paediatrics and Child Health (NICE 66)
Evidence submitted by the Royal College of
Psychiatrists (NICE 22)
Evidence submitted by the Royal National
Institute of the Blind (RNIB) (NICE 63)
Evidence submitted by Sanofi-aventis (NICE
57)
Evidence submitted by Schering Health Care
Limited (NICE 56)
Evidence submitted by ScotME (NICE 91)
Evidence submitted by Servier Laboratories
(NICE 41)
Evidence submitted by Sirtex Medical (NICE
54)
Evidence submitted by the South Asian Health
Foundation (NICE 12)
Evidence submitted by the Specialised Healthcare
Alliance (NICE 80)
Evidence submitted by Wyeth Pharmaceutical
(NICE 88)
Evidence submitted by Dr Daphine Austin (NICE
20)
Evidence submitted by Professor Michael Barkham
and others (NICE 83)
Evidence Submitted by Dr Imogen Evans, Mrs
Hazel Thornton and Sir Iain Chalmers (NICE 21)
Evidence submitted by Professor Malcolm Hooper
(NICE 07)
Evidence submitted by Dr Chris Hyde (NICE
76)
Evidence submitted by Doris Jones (NICE 37)
Evidence submitted by Gay Lee (NICE 03)
Evidence submitted by Michael Lee (NICE 13)
Evidence submitted by Professor Ragnar Lofstedt
and Frederic Bouder, King's College London (NICE 31)
Evidence submitted by Dr Tom Marshall, University
of Birmingham (NICE 05)
Evidence submitted by Dr Catherine Meads,
University of Birmingham (NICE 08)
Evidence submitted by Sandra Simkin (NICE
50)
Evidence submitted by Dr Keith Syrett, University
of Bristol (NICE 48)
Evidence submitted by Peter Telford (NICE
32)
Evidence submitted by Mr David Thomson (NICE
16)
Evidence submitted by John Walsh (NICE 09)
Evidence submitted by Miss Rose A Woodward
(NICE 98)
Pelvic Pain Support Network (NICE 04)
| 
